<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20160307026950N50</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-01-01</date_registration>
      <primary_sponsor>Esfahan University of Medical Sciences</primary_sponsor>
      <public_title>Effect of gargling rosemary extract and Ketamine on hoarseness and sore throat</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of the effect of gargling rosemary extract and Ketamine on hoarseness and sore throat after tracheal intubation</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-12-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>120</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/67426</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Triple blinded, Placebo: Used, Assignment: Parallel, Purpose: Prevention, Randomization description: Randomization is done in a simple way so that the patients are entered into groups A, B, and C according to the time of their arrival in the operating room, and this will continue until the number of patients in each group reaches 40 people, Blinding description: This is a three-way blind clinical trial; In this way, the researcher who records the patient's symptoms is different from the person who prescribes the drug and has no knowledge of the type of drug and is blind. The analysts who analyze the data collected during the study also know the type of intervention. They don't have it in any group and they are blind. Even though the patients are included in the study, they do not know the type of intervention and are blind.</study_design>
      <phase>3</phase>
      <hc_freetext>Sore throat and Hoarseness after endotracheal intubation.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group A: In this group of patients, before induction of anesthesia, 30 drops of Rosemary solution (manufactured by Fadek Sepahan Pharmaceutical Company) dissolved in 30 ml of distilled water are gargled for 2-3 minutes, then 5 mg/kg Thiopental is administered to induce anesthesia. Sodium manufactured by Elixir Pharmaceutical Company, 100 Micrograms of fentanyl manufactured by Caspin Pharmaceutical Company, and 0.5 mg/kg of Atracurium manufactured by Aburihan Pharmaceutical Company is injected. Sampling and recording of symptoms are also done during and after anesthesia. Intervention 2: Intervention group B: In this group, patients gargle 40 mg of Ketamine dissolved in 30 ml of distilled water for 30 seconds before induction of anesthesia, then 5 mg/kg Thiopental is administered to induce anesthesia. Sodium manufactured by Elixir Pharmaceutical Company, 100 Micrograms of fentanyl manufactured by Caspin Pharmaceutical Company, and 0.5 mg/kg of Atracurium manufactured by Aburihan Pharmaceutical Company is injected. Sampling and recording of symptoms are also done during and after anesthesia. Intervention 3: Control group C: In this group, patients gargle 30 ml of distilled water for 2-3 minutes before induction of anesthesia, then 5 mg/kg Thiopental is administered to induce anesthesia. Sodium manufactured by Elixir Pharmaceutical Company, 100 Micrograms of fentanyl manufactured by Caspin Pharmaceutical Company, and 0.5 mg/kg of Atracurium manufactured by Aburihan Pharmaceutical Company is injected. Sampling and recording of symptoms are also done during and after anesthesia.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no more information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Roza Bidkalameh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Hezar Jarib</address>
        <city>Isfahan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8146713543</zip>
        <telephone>+98 31 3620 2020</telephone>
        <email>rozabidkalame94@gmail.com</email>
        <affiliation>Esfahan University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Behzad Nazem roaya</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Hezar Jarib</address>
        <city>Isfahan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8146713543</zip>
        <telephone>+98 31 3620 2020</telephone>
        <email>behzad_nazem@med.mui.ac.ir</email>
        <affiliation>Esfahan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients 18 to 65 years old
Anesthesia class I and II according to ASA criteria
Candidate for general anesthesia with tracheal intubation
Informed consent to enter the study</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>65 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Addiction to cigarettes and drugs
Allergic to rosemary and Ketamine
Diabetes
Asthma and airway problems</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Prevention</i_code>
      <i_code>Prevention</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group A: In this group of patients, before induction of anesthesia, 30 drops of Rosemary solution (manufactured by Fadek Sepahan Pharmaceutical Company) dissolved in 30 ml of distilled water are gargled for 2-3 minutes, then 5 mg/kg Thiopental is administered to induce anesthesia. Sodium manufactured by Elixir Pharmaceutical Company, 100 Micrograms of fentanyl manufactured by Caspin Pharmaceutical Company, and 0.5 mg/kg of Atracurium manufactured by Aburihan Pharmaceutical Company is injected. Sampling and recording of symptoms are also done during and after anesthesia.</i_keyword>
      <i_keyword>Intervention group B: In this group, patients gargle 40 mg of Ketamine dissolved in 30 ml of distilled water for 30 seconds before induction of anesthesia, then 5 mg/kg Thiopental is administered to induce anesthesia. Sodium manufactured by Elixir Pharmaceutical Company, 100 Micrograms of fentanyl manufactured by Caspin Pharmaceutical Company, and 0.5 mg/kg of Atracurium manufactured by Aburihan Pharmaceutical Company is injected. Sampling and recording of symptoms are also done during and after anesthesia.</i_keyword>
      <i_keyword>Control group C: In this group, patients gargle 30 ml of distilled water for 2-3 minutes before induction of anesthesia, then 5 mg/kg Thiopental is administered to induce anesthesia. Sodium manufactured by Elixir Pharmaceutical Company, 100 Micrograms of fentanyl manufactured by Caspin Pharmaceutical Company, and 0.5 mg/kg of Atracurium manufactured by Aburihan Pharmaceutical Company is injected. Sampling and recording of symptoms are also done during and after anesthesia.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Severity of sore throat. Timepoint: 1 hour after recovery and 6, 12, 24 and 48 hours after that. Method of measurement: Scoring from 0 to 10 based on pain intensity.</prim_outcome>
      <prim_outcome>Severity of hoarseness. Timepoint: 1 hour after recovery and 6, 12, 24 and 48 hours after that. Method of measurement: Scoring from 0 to 3 based on the severity of hoarseness.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Blood Pressure. Timepoint: From the time of induction of anesthesia until the end of recovery. Method of measurement: sphygmomanometer.</sec_outcome>
      <sec_outcome>Heart Rate. Timepoint: From the time of induction of anesthesia until the end of recovery. Method of measurement: Electrocardiogram.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Esfahan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-05-15</approval_date>
        <contact_name>Ethics Committee in Biomedical Research, Isfahan University of Medical Sciences</contact_name>
        <contact_address>Hezar Jarib Isfahan Isfehan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
